Valeant Pharmaceuticals International (VRX) Posts Q1 EPS of $0.02, Tops Revenue Expectations and Raises FY11 Guidance
Tweet
Share
E-mailGet Alerts VRX Hot Sheet
Price: $23.40 --0%
Financial Fact:
Net income attributable to Valeant: 32.25M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Financial Fact:
Net income attributable to Valeant: 32.25M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) reported Q1 EPS of $0.02, versus ($0.02) reported last year. Revenue for the quarter came in at $565 million versus the consensus estimate of $297.08 million.
Valeant Pharmaceuticals International, Inc. raised it FY2011 EPS guidance to $2.65-$2.90 from $2.45-$2.70.
Valeant Pharmaceuticals International, Inc. raised it FY2011 EPS guidance to $2.65-$2.90 from $2.45-$2.70.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- lululemon athletica (LULU) Tops Q2 EPS by $1.10, Cuts Guidance
- Duluth Holdings Inc. (DLTH) Tops Q2 EPS by 49c
- Campbell Soup (CPB) Reports In-Line Q4 EPS, Misses on Revenue; Offers FY27 EPS Guidance
Create E-mail Alert Related Categories
Earnings, Hot GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
